Siena, Italy, 27 July 2026 – Philogen S.p.A. (BIT:PHIL) is pleased to announce the submission of an updated Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the approval of Nidlegy™, an investigational product for the neoadjuvant treatment of adult patients with locally advanced, fully resectable melanoma.